About 130 million US adults have hypertension,1 yet fewer than half have controlled blood pressure (BP), which has worsened in recent years.2 For quite some time, hypertension seemed to be considered a “solved” problem that was ignored by the world of pharmacologic research and development. The last time a new class of antihypertensive medication was approved by the US Food and Drug Administration (FDA) was direct renin inhibitors in 2007, which have not panned out to be particularly effective or well tolerated over existing therapies.